Semax Dosage (5 mg Vial) Protocol

Use one complete set of measured and sterile research supplies for each prepared Semax 5 mg nasal bottle.

• Semax 5 mg research vial: One vial per prepared bottle. The product gallery below links to the existing Semax 5 mg supplier page.
• Sterile research vehicle: Single-use sterile 0.9% sodium chloride for the worked saline example, or another validated sterile nasal research vehicle.
• Sterile nasal actuator bottle: One 5 mL or 10 mL bottle intended for single-user research.
• Metered pump: A compatible actuator documented or verified at 0.10 mL per complete spray.
• Calibrated transfer tools: Sterile syringes or pipettes that can measure the initial 3.0 mL and the exact 5.0 mL or 10.0 mL final volume.
• Sterile transfer needle: Required when the peptide vial uses a rubber septum.
• Clean handling supplies: Alcohol preparation pads, clean gloves, and a disinfected work surface.
• Label and research log: Record the peptide amount, final volume, concentration, pump output, preparation date, priming sprays, and actuation count.
• Storage materials: Light-protective refrigerated storage appropriate to the validated formulation.
• Sharps container: Use when transfer needles are part of the preparation workflow.

View Supplier

• Primary human research route: Intranasal drops or measured intranasal solution.
• 5 mL final volume: 1 mg/mL, 100 mcg per verified 0.10 mL spray, and 50 nominal sprays.
• 10 mL final volume: 0.5 mg/mL, 50 mcg per verified 0.10 mL spray, and 100 nominal sprays.
• Device check: Confirm the pump output and follow its priming instructions before using the calculation.
• Research context: Published amounts varied by study population, formulation, and research objective.

Semax is a synthetic heptapeptide based on the ACTH(4-10) sequence. Human research has evaluated intranasal Semax in healthy volunteers and in condition-specific neurological studies^[1][2][3]. The calculations below use the entire 5 mg vial and keep published study protocols separate from worked preparation examples.

This exact-strength Semax dosing guide keeps Semax 5 mg dosage calculations separate from the broader Semax family page. It converts the full 5,000 mcg vial into two measured spray concentrations while preserving the established dosing schedule.

• Human research route: Intranasal drops or measured intranasal solution.
• Peptide amount: 5,000 mcg total in the vial.
• 5 mL option: 1,000 mcg/mL and 100 mcg per verified 0.10 mL spray.
• 10 mL option: 500 mcg/mL and 50 mcg per verified 0.10 mL spray.
• Final-volume rule: Bring the transferred solution to an exact measured final volume.
• Product provenance: The approved Pure Lab Peptides page supports the 5 mg vial identity and batch-documentation context, not clinical efficacy claims^[8].

The conversion depends on the measured final volume and the verified amount of liquid released by one complete pump stroke. A bottle label or nominal capacity does not establish either variable.

• 200 mcg: 2 sprays at 5 mL or 4 sprays at 10 mL.
• 300 mcg: 3 sprays at 5 mL or 6 sprays at 10 mL.
• 400 mcg: 4 sprays at 5 mL or 8 sprays at 10 mL.
• 500 mcg: 5 sprays at 5 mL or 10 sprays at 10 mL.
• Interpretation: These are reconstitution-math equivalents, not a recommended Semax dose. Match each research dose to its original study context.

Storage depends on the complete formulation, container, preservative system, and handling method. The registered 0.1% drop instructions and a custom research preparation are not interchangeable^[4].

• Registered 0.1% product: Protected from light, stored at no more than 10 degrees C, and not frozen.
• Custom research preparation: Use formulation-specific stability and microbiological controls.
• Labeling: Record preparation date, final volume, concentration, vehicle, pump output, and storage conditions.
• Handling: Keep the cap secured and minimize unnecessary warming and light exposure.

Human Semax research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable.

The 5 mL calculation above also produces 1 mg/mL, which matches the concentration of the registered 0.1% drop formulation. The device and formulation are still different, so concentration equivalence does not establish identical delivery, stability, or dosing.

A 0.10 mL actuator is a common nasal pump configuration, but pump output is not universal. Pharmaceutical literature reports pump volumes from approximately 0.025 mL to 0.20 mL per spray^[5]. Use the manufacturer specification or a validated measurement for the exact device.

Core Formula

mcg per spray = (5,000 mcg / final volume in mL) x verified mL per spray

nominal sprays = final volume in mL / verified mL per spray

Actuator Checks Before Recording a Result

• Confirm the stated volume per full actuation for the specific pump.
• Follow the documented priming and repriming procedure.
• Record residual volume and tail-off near bottle exhaustion when estimating usable sprays.
• Keep pump orientation and actuation stroke consistent during the research procedure.

FDA nasal spray guidance treats pump delivery, priming, dose uniformity, and bottle exhaustion as product performance variables^[6].

For this Semax 5 mg protocol, reconstitution and final-volume adjustment are separate measurement events. The vial first receives 3.0 mL of the selected compatible sterile vehicle. After complete dissolution and transfer, more vehicle is added until the bottle reaches exactly 5.0 mL or 10.0 mL.

• 5 mL final volume: 5,000 mcg divided by 5 mL equals 1,000 mcg/mL.
• 10 mL final volume: 5,000 mcg divided by 10 mL equals 500 mcg/mL.
• 0.10 mL actuator: Multiply the concentration by 0.10 mL to obtain 100 mcg or 50 mcg per complete spray.
• Priming and residual volume: The theoretical 50-spray or 100-spray yield is a nominal calculation before priming, repriming, and bottle hold-up.

Nasal-device literature identifies pump output, priming, plume formation, dose uniformity, and bottle exhaustion as product-performance variables, so the device must be verified rather than assumed^[5][6].

Small volume and device differences can materially change the calculated amount delivered per spray.

• Use a measured final volume, not the bottle capacity mark alone.
• Verify that the actuator releases 0.10 mL per full stroke before applying the main table.
• Prime and reprime exactly as specified for the pump, then record those actuations.
• Keep the bottle in the documented orientation and use a complete, consistent stroke for each recorded spray.
• Treat the theoretical 50 or 100 sprays as nominal counts because priming and residual hold-up consume part of the volume.
• Use a validated laboratory handling and stability plan for any custom multidose preparation.

Semax is a synthetic peptide based on the ACTH(4-10) sequence and was developed without the hormonal activity of full-length ACTH. This nootropic peptide has been studied for effects involving brain-derived neurotrophic factor (BDNF), neuroprotection, attention, memory, cognitive performance, functional connectivity, and condition-specific neurological outcomes^[1][2][3][7].

Intranasal delivery places a measured solution on the nasal mucosa, the route used in the human studies summarized here. The vial calculation itself is concentration based: divide 5,000 mcg by the measured final volume for mcg per mL, then multiply by verified pump output for mcg per spray.

Mechanistic and translational findings do not establish that a custom 5 mg research vial, a registered preserved drop product, N-acetyl Semax, and every experimental formulation have identical delivery or stability. Each source must be interpreted according to its population, formulation, route, and study design^[7].

Human Semax findings cover several research settings, but they do not form one universal dose range, dosing protocol, or safety standard. Potential benefits and cognitive effects must be interpreted within the design of each study.

• Healthy-volunteer studies reported changes in attention, operator performance, EEG measures, or functional connectivity after intranasal exposure^[1][2].
• Condition-specific studies evaluated neurological recovery and other outcomes using protocols and formulations that differ from the 5 mg calculation on this page^{[3][10][11][12]}.
• The registered 0.1% product information reports possible mild nasal irritation with prolonged use^[4].
• FDA safety data identify significant safety concerns associated with certain compounded bulk substances, including Semax. Semax is not FDA approved, and that regulatory context is distinct from an approval of a specific research-vial protocol^[9].
• Pump output, formulation, nasal condition, and technique can affect delivered amount and deposition pattern^[5][6].

Consistent device and recording procedures improve the value of research observations.

• Pump specification: Record the stated or measured mL per actuation.
• Priming status: Document first use, repriming, and any missed sprays.
• Actuation technique: Keep bottle orientation, stroke length, and stroke force consistent.
• Nasal condition: Record congestion, irritation, or other conditions that could affect deposition.
• Formulation details: Record the vehicle, final volume, concentration, container, and storage conditions.
• Actuation count: Track sprays from priming through final use to identify tail-off and residual volume.

Use a standardized device procedure so the recorded volume remains consistent across research observations.

1. Inspect the labeled concentration and confirm the actuator output before use.
2. Prime or reprime the pump according to the manufacturer instructions.
3. Keep the bottle in the specified orientation and use one complete, smooth stroke.
4. Record each actuation immediately, including priming sprays.
5. Wipe the nozzle with a clean material appropriate for the device and replace the cap.
6. Return the bottle to its documented storage condition after the research procedure.

How is a Semax 5 mg vial calculated for a nasal research bottle?

The full vial contains 5,000 mcg. A measured 5 mL final volume equals 1,000 mcg/mL, while 10 mL equals 500 mcg/mL. The amount per spray depends on the verified mL released by the actuator.

How much sterile vehicle is used for the Semax 5 mg example?

The seven-step preparation first adds 3.0 mL to the vial. After dissolution and complete transfer, additional vehicle brings the nasal bottle to an exact measured final volume of 5.0 mL or 10.0 mL. The final-volume measurement controls the concentration.

How many sprays are in a 5 mg Semax bottle?

At a verified 0.10 mL per spray, 5 mL provides 50 nominal sprays and 10 mL provides 100 nominal sprays. Usable yield may be lower because priming, repriming, and residual volume consume liquid.

Does a 1 mg/mL concentration make a custom preparation equivalent to registered Semax drops?

No. Matching one concentration does not establish equivalent formulation, preservative system, device delivery, stability, or approved use^[4].

Why must the nasal pump output be verified?

Nasal pumps can release different volumes. The calculator assumes 0.10 mL only when that output is documented or measured for the specific actuator^[5][6].

Is this a standard Semax dosage or clinical recommendation?

No. The Semax peptide dosing chart preserves the page’s research schedule and shows calculation examples for a 5 mg vial. It does not establish an optimal Semax dose, a universal Semax protocol, or medical advice.

This content is for educational purposes only and is not medical advice.

• 1
  Kaplan et al. (1996) Synthetic ACTH analogue Semax displays nootropic-like activity in humans. Reports intranasal healthy-volunteer experiments, including physiological solution context.

  View Source
• 2
  Lebedeva et al. (2018) Effects of Semax on the default mode network of the brain. Healthy-volunteer fMRI study using a single 1.2 mg intranasal exposure.

  View Source
• 3
  Gusev et al. (2018) Efficacy of Semax in patients at different stages of ischemic stroke.

  View Source
• 4
  RLSnet Semax 0.1% product instructions based on the manufacturer-approved instruction.

  View Source
• 5
  Trows et al. (2014) Analytical challenges and regulatory requirements for nasal drug products in Europe and the United States.

  View Source
• 6
  U.S. Food and Drug Administration Nasal spray product guidance covering pump delivery, priming, dose uniformity, and performance.

  View Source
• 7
  Deigin et al. (2022) Development of peptide biopharmaceuticals in Russia. Academic review of Semax development, formulation, and research context.

  View Source
• 8
  Pure Lab Peptides Semax 5 mg research product page and batch-documentation context.

  View Source
• 9
  U.S. Food and Drug Administration Safety information for certain bulk substances used in compounding, including Semax.

  View Source
• 10
  Nasution et al. (2013) ACTH(4-10)Pro8-Gly9-Pro10 in moderate head injury.

  View Source
• 11
  Therapy of peptic ulcer with Semax peptide (2002) Intranasal Semax added to conventional therapy.

  View Source
• 12
  Motor neuron disease Semax study (2008) Open-label intranasal research with two 10-day courses.

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.